Renew Biotechnologies Unifies Wasatch BioLabs and Resonant Under One Brand
Renew Biotechnologies announced the consolidation of Wasatch BioLabs and Resonant under its single brand to advance sequencing-based diagnostics and clinical testing.
Renew Biotechnologies announced on July 9, 2026, that it has consolidated its subsidiaries, Wasatch BioLabs and Resonant, under the Renew Biotechnologies brand. This strategic move aims to create a unified platform for advancing sequencing-based diagnostics, translational research, and clinical testing.
The consolidation is intended to provide clients, partners, and researchers with clearer access to Renew's integrated capabilities, which span advanced sequencing, assay development, diagnostic product development, and laboratory infrastructure. The company clarified that this is a brand consolidation and not a merger, acquisition, or ownership change. Existing services and operations will continue uninterrupted under the Renew brand.
"Renew Biotechnologies is building a platform designed to make complex biology more measurable, actionable, and clinically useful," said CEO Chad Pollard. "Bringing our brands together under Renew better reflects who we are today and where we are going as a company. This is an exciting next step that strengthens how we communicate our capabilities, accelerate innovation, and translate advanced molecular technologies into real-world clinical impact."
Wasatch BioLabs, founded in 2022, has developed expertise in long-read and native-read sequencing, translational research, and custom assay development. Resonant has focused on sequencing-based diagnostics, including NeuroLens®, a blood-based liquid biopsy test for conditions like Alzheimer's disease. Together, these capabilities now operate as a single platform supporting partners from biomarker discovery through clinical implementation.
The unified Renew Biotechnologies will continue to expand services in various areas, including RNA therapeutic quality control, methylation technologies, pharmacogenomics, and blood-based diagnostics. The company's new website serves as the single destination for its sequencing services, clinical laboratory capabilities, and product portfolio.